7-(R,S)-aminooctanoic acid | 7450-65-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-(R,S)-aminooctanoic acid
• 英文别名: 7-Aminooctanoic acid
• CAS: 7450-65-9
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: KMEQXYJELYYJGF-UHFFFAOYSA-N

物化性质

• 熔点：
  206 °C
• 沸点：
  278.7±23.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(R,S)-aminooctanoic acid 在 甲醇 、 lithium hydroxide 、 正丁基锂 、 2,4,6-三异丙基苯磺酰叠氮化物 、 双氧水 、 双(三甲基硅烷基)氨基钾 、 碳酸氢钠 、 三乙胺 、 tin(ll) chloride 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 ((S)-6-Amino-1-methyl-7-oxo-7-piperidin-1-yl-heptyl)-carbamic acid benzyl ester
  参考文献：
  名称：

  Selectivity enhancement induced by substitution of non-natural analogues of arginine and lysine in arginine-based thrombin inhibitors

  摘要：

  Seven non-natural analogues of arginine and lysine have been substituted in an established arginine-based thrombin inhibitor. Four of the new compounds exhibited significant thrombin inhibition (K-i's 0.53-3.95 muM) and were subsequently tested for selectivity against trypsin. The two best compounds gave selectivity ratios of 962 and 525 (trypsin/thrombin), improving upon the parent compound. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00328-6
• 作为产物：
  描述：

  2-乙酰基环己酮 在 sodium hydroxide 、 sodium cyanoborohydride 、 溴化铵 作用下， 生成 7-(R,S)-aminooctanoic acid
  参考文献：
  名称：

  Asymmetric synthesis of non-natural homologues of lysine

  摘要：

  A series of non-natural amino acid homologues of L- and D-lysine have been synthesized and protected for use in solid-phase peptide synthesis. With these residues, electrostatics and hydrophobicity of peptides can be enhanced or altered. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00335-1

文献信息

• [EN] PHOTOCHROMIC XANTHENE FLUOROPHORES AND THEIR UTILITY IN LIVE-CELL IMAGING BEYOND THE DIFFRACTION LIMIT<br/>[FR] FLUOROPHORES DE XANTHÈNE PHOTOCHROMIQUES ET LEUR UTILITÉ DANS L'IMAGERIE DE CELLULES VIVANTES AU-DELÀ DE LA LIMITE DE DIFFRACTION
  申请人：HUGHES HOWARD MED INST

  公开号：WO2018182811A1

  公开（公告）日：2018-10-04

  The present invention is generally directed to novel fluorophores and their use in imaging methods. In one case, the present invention provides a compound according to the structure shown in FIG. 20A. In another case, the present invention provides a method of imaging one or more cellular structures within one or more cells using a compound of the structure shown in FIG. 20A.

  本发明通常涉及新型荧光物质及其在成像方法中的应用。在一种情况下，本发明提供了一种符合图20A所示结构的化合物。在另一种情况下，本发明提供了一种利用图20A所示结构的化合物成像一个或多个细胞内的一个或多个细胞结构的方法。
• [EN] DRUG CONJUGATES<br/>[FR] CONJUGUÉS DE MÉDICAMENT
  申请人：UNIV MISSOURI

  公开号：WO2009158633A1

  公开（公告）日：2009-12-30

  Conjugated compounds comprising a therapeutic or diagnostic agent linked to a substrate for a cell membrane transporter or receptor by lipophilic linker are provided.

  提供了包含治疗或诊断药物与细胞膜转运体或受体的底物通过亲脂性连接剂连接的共轭化合物。
• PEPTIDES, METHOD FOR ASSAYING HUMAN PEPSINOGEN II or HUMAN PEPSIN II, AND ASSAYING KIT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1046650A1

  公开（公告）日：2000-10-25

  A peptide of the formula (I) (wherein each symbol is as defined in the description.) or an acid addition salt thereof. A compound of the formula (I) is a specific substrate for human pepsin II, so it can be used for assaying human pepsin II or human pepsinogen II and it is useful for diagnosis of gastric diseases such as gastric cancer and gastric ulcer.

  式(I)的多肽 (其中各符号如描述中所定义。） 或其酸加成盐。 式（I）化合物是人类胃蛋白酶 II 的特异性底物，因此可用于检测人类胃蛋白酶 II 或人类胃蛋白酶原 II，并可用于胃癌和胃溃疡等胃部疾病的诊断。
• Photochromic xanthene fluorophores and their utility live-cell beyond the diffraction limit
  申请人：HOWARD HUGHES MEDICAL INSTITUTE

  公开号：US11067566B2

  公开（公告）日：2021-07-20

  The present invention is generally directed to novel fluorophores and their use in imaging methods. In one case, the present invention provides a compound according to the structure shown in FIG. 20A. In another case, the present invention provides a method of imaging one or more cellular structures within one or more cells using a compound of the structure shown in FIG. 20A.

  本发明一般涉及新型荧光团及其在成像方法中的应用。在一种情况下，本发明提供了一种按照图 20A 所示结构的化合物。在另一种情况下，本发明提供了一种使用图 20A 所示结构的化合物对一个或多个细胞内的一个或多个细胞结构成像的方法。
• Manufacture and use of an antibiotic/antibiotics preparation
  申请人：Heraues Kulzer GmbH & Co.KG

  公开号：US20020183265A1

  公开（公告）日：2002-12-05

  The present invention concerns the manufacture and use of an antibiotic/antibiotics preparation for human and veterinary medicine, for the treatment of local microbial infections in hard and soft tissue. The manufacture in accordance with the invention of an antibiotic/antibiotics preparation takes place according to the invention in that water, an amphiphilic component of a representative of the alkyl sulfates, aryl sulfates, alkylaryl sulfates, cycloalkyl sulfates, alkylcycloalkyl sulfates, alkyl sulfamates, cycloalkyl sulfamates, alkylcycloalkyl sulfamates, aryl sulfamates, alkylaryl sulfamates, alkyl sulfonates, fatty acid-2-sulfonates, aryl sulfonates, alkylaryl sulfonates, cycloalkyl sulfonates, cycloalkyl sulfonates, alkylcycloalkyl sulfonates, alkyl disulfates, cycloalkyl disulfates, alkyl disulfonates, cycloalkyl disulfonates, aryl disulfonates, alkylaryl disulfonates, aryl trisulfonates and alkylaryl trisulfonates, one or more antibiotic components from the group of aminoglycoside antibiotics, lincosamide antibiotics and tetracycline antibiotics, an organic auxiliary component and/or an inorganic auxiliary component and if need be at least one biologically active component are mixed together and shaped into molded elements, granulates, powders, foils, shaped masses and threads.

  本发明涉及一种用于治疗硬组织和软组织局部微生物感染的人类和兽医抗生素/抗生素制剂的制造和使用。烷基环烷基硫酸盐、烷基氨基磺酸盐、环烷基氨基磺酸盐、烷基环烷基氨基磺酸盐、芳基氨基磺酸盐、烷芳基氨基磺酸盐、烷基磺酸盐、脂肪酸-2-磺酸盐、芳基磺酸盐、烷芳基磺酸盐、环烷基磺酸盐、环烷基磺酸盐、烷基环烷基磺酸盐、烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐、环烷基二硫酸盐烷基二磺酸盐、环烷基二磺酸盐、烷基二磺酸盐、环烷基二磺酸盐、芳基二磺酸盐、 烷芳基二磺酸盐、芳基三磺酸盐和烷芳基三磺酸盐； 氨基糖苷类抗生素中的一种或多种抗生素成分、林可酰胺类抗生素和四环素类抗生素中的一种或多种抗生素成分、一种有机辅助成分和/或一种无机辅助成分，必要时还包括至少一种生物活性成分。